Radionuclide News and Research

RSS

La Jolla Institute forms partnership to investigate potential new therapy for sickle cell disease

Researchers from the La Jolla Institute for Allergy & Immunology have joined forces with the Dana-Farber Cancer Institute in Boston and Washington University in St. Louis to investigate a potential new therapy for sickle cell disease, a severe and chronic illness affecting more than 70,000 Americans and several million people worldwide.

21 Jul 2010

Bone samples act as the ultimate biomarker for environmental pollution: Researchers

Exposure to chemical pollutants is of growing concern to regulators, health workers, and environmentalist groups alike. Now, researchers in the US and Russia have demonstrated that samples of human bone can act as a biological marker for dozens of metals and toxic elements across the periodic table. They describe details in a study published in the International Journal of Environment and Health.

18 Jun 2010

Immunomedics reports encouraging results from TF2 Phase I studies for colorectal cancer

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that TF2, a proprietary bispecific antibody, has shown selective tumor localization and minimal normal tissue retention in two early Phase I studies in patients with colorectal cancer.

8 Jun 2010

AACE, AME and ETA jointly publish guidelines for diagnosis and management of thyroid nodules

Three of the world's most respected medical associations for the treatment of thyroid disease recently issued joint guidelines for the diagnosis and management of thyroid nodules. The American Association of Clinical Endocrinologists, the Associazione Medici Endocrinologi and European Thyroid Association jointly published the guidelines online this week, and the executive summary will be published in the next issue of their respective journals.

20 May 2010

High dose B-vitamin therapy slows progression of diabetic nephropathy: Study

Patients with diabetic nephropathy (kidney disease caused by diabetes) who received high dose B-vitamin therapy experienced a more rapid decline in kidney function and had a higher rate of heart attack and stroke than patients who received placebo, according to a study in the April 28 issue of JAMA.

28 Apr 2010

YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR

YM BioSciences Inc., today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 17-21 in Washington, DC. The first poster describes the results of the previously reported collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The poster will describe activity of 111In-NLS-nimotuzumab against breast cancer cells with high and low EGFR expression.

15 Mar 2010

Springer to publish Nuclear Medicine and Molecular Imaging

NMMI publishes original research papers, reviews, case reports, editorials and letters to the editor on nuclear medicine and a wide range of related sciences. These include radiochemistry, radiopharmacy, dosimetry and pharmacokinetics/pharmacodynamics of radiopharmaceuticals, nuclear and molecular imaging analysis, nuclear and molecular imaging instrumentation, radiation biology and radionuclide therapy. June-Key Chung, MD, PhD, from the Seoul National University College of Medicine will serve as editor-in-chief. He will be supported by an international editorial board.

10 Mar 2010

YM BioSciences announces results of cancer antibody-radionuclide conjugate development collaboration

YM BioSciences Inc. today announced results of a collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The approach has successfully concluded its first series of proof-of-principle experiments establishing promise for future development and application.

12 Jan 2010

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively guide prostate cancer therapy targeting and dosing and is a significant predictor of disease free survival, according to data presented on Tuesday, November 3, 2009 at the 51st American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting in Chicago, Illinois.

4 Nov 2009

Researchers report preclinical results of a novel PET biomarker designed to detect malignant breast tumors

Researchers at Thomas Jefferson University in Philadelphia, PA, supported in part by NuView Life Sciences, have published an article in the Journal of Nuclear Medicine reporting preclinical results of a novel PET biomarker designed to selectively detect malignant breast tumors.

30 Oct 2009

Study finds lung scintigraphy more reliable than CTA for pulmonary embolism diagnosis in pregnant patients

A medical imaging procedure known as lung scintigraphy may be more reliable than pulmonary CT angiography (CTA) for identifying or excluding pulmonary embolism (PE) in pregnant patients, according to a study published in the November issue of the American Journal of Roentgenology.

21 Oct 2009

Albumin for cancer treatment

Tiny particles of albumin, a protein found in the blood, can be used to carry radioactive isotopes to the site of a cancerous tumour in the body and so avoid many of the side-effects of conventional radiotherapy.

16 Sep 2009

Non-toxic radioactive patch successfully treats skin cancer

A new study shows that a radioactive skin patch can safely and successfully treat basal cell carcinoma, one of the most common types of skin cancers, according to researchers at the SNM's 56th Annual Meeting. The skin patch, which delivers the radioactive phosphorus-32, is nontoxic and could be an excellent alternative to surgery or radiotherapy in cases where carrying out these treatments is difficult.

15 Jun 2009

Molecular imaging enables earlier, individualized treatment of thyroid cancer

In a study to determine the diagnostic value of molecular imaging in nodal staging of patients with thyroid cancer, researchers were able for the first time to accurately distinguish between cancerous cells in regional lymph nodes and normal residual thyroid tissue directly after surgery.

5 Jan 2009

Discovery of molecule that targets brain tumors

UC Davis Cancer Center researchers report today the discovery of a molecule that targets glioblastoma, a highly deadly form of cancer.

30 Dec 2008

Radioimmunotherapy targeting viral antigens shows potential to treat or prevent viral cancers

A new study, presented at the Society of Nuclear Medicine's 55th Annual Meeting, shows that radioimmunotherapy (RIT) targeting viral antigens offers a novel option to treat-or even prevent-many viral cancers by targeting cancer cells expressing viral antigens or infected cells before they convert into malignancy.

16 Jun 2008

Nuclear medicine imaging test could aid children suffering from reflux disease

A nuclear medicine imaging test was used to confirm that children with respiratory problems may be more likely to develop gastroesophageal reflux disease, according to researchers at Society of Nuclear Medicine's 55th Annual Meeting.

16 Jun 2008

PET/CT imaging proves golden for detecting cancer in children

PET/CT imaging exhibits significantly higher sensitivity, specificity and accuracy than conventional imaging when it comes to detecting malignant tumors in children, according to research published in the December issue of the Journal of Nuclear Medicine.

13 Dec 2007

Quantitative PET imaging finds early determination of effectiveness of cancer treatment

With positron emission tomography (PET) imaging, seeing is believing: Evaluating a patient's response to chemotherapy for non-Hodgkin lymphoma (NHL) typically involves visual interpretation of scans of cancer tumors.

24 Oct 2007

New device ensures nuclear medicine safer than ever

Hospitals are now able to ensure that the correct dose is administered to the 670,000 patients that undergo nuclear medicine procedures every year due to a new device developed by scientists at the National Physical Laboratory (NPL).

10 Oct 2007